GlaxoSmithKline PLC
featured
Simon Dingemans, Chief Financial Officer at GlaxoSmithKline says that the company's re-engineered approach to R&D is bearing fruit with pipeline looking very healthy.
» Read More
More
-
CHICAGO, May 23- Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.
-
LONDON, May 22- The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism.
-
LONDON, May 22- The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism.
-
*Potential sales of $35 bln a year over next 10 years- Citigroup. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers Squibb and Roche Holding.
-
*Bid raised to $12.50/ share from $11.25. DUBLIN/ NEW YORK, May 20- Royalty Pharma raised its hostile bid for Elan to $12.50 per share and threatened to withdraw the bid if Elan shareholders approve a series of defensive transactions announced by the Irish drug firm. Royalty previously offered $11.25 a share.
-
DUBLIN, May 20- Royalty Pharma raised its hostile bid for Elan to $12.50 per share and heaped pressure on shareholders, saying it will withdraw the bid if they approve a series of defensive transactions announced by the Irish drug firm.
-
DUBLIN, May 20- Elan announced its second major drug deal inside a week on Monday and said it would buy back more shares as it continues to bat against a $5.7 billion takeover bid from U.S. investor Royalty Pharma.
-
SANTA CLARA, Calif.-- Drug developer XenoPort said Friday that its treatment for restless leg syndrome, Horizant, will likely be available to U.S. patients in early June. Last month XenoPort Inc. said that there was a shortage of Horizant, with patients telling them that they were unable to fill prescriptions.
-
NEW YORK, May 16- The big four U.S. broadcast networks, in need of new TV hits to turn around slumping ratings, are betting espionage programs and old comedy stars will convince advertisers to spend about $9 billion during the so-called upfront selling season.
-
WILLIAMSBURG, Va.-- Changes in the marketplace have forced the public health community to wrestle with the idea that some tobacco products may pose less of a health risk than others, the new head of the Food and Drug Administration's tobacco control efforts told an industry group on Thursday.
-
LONDON, May 16- On approaching his 60th birthday this year, long-serving Tullow Oil boss Aidan Heavey told staff he felt "like two 30 year-olds". Peter Voser is giving up one of the world's most challenging CEO roles at Royal Dutch/Shell next year, before his 55th birthday, in pursuit of a "lifestyle change".
-
LONDON, May 16- On approaching his 60th birthday this year, long-serving Tullow Oil boss Aidan Heavey told staff he felt "like two 30 year-olds". Peter Voser is giving up one of the world's most challenging CEO roles at Royal Dutch/Shell next year, before his 55th birthday, in pursuit of a "lifestyle change".
-
Simon Dingemans, Chief Financial Officer at GlaxoSmithKline says that the company's re-engineered approach to R&D is bearing fruit with pipeline looking very healthy.
-
Yum Brands falls as monthly Chinese sales drop. NEW YORK, May 13- U.S. stocks closed little changed on Monday, pausing after hitting record highs last week, but strength in healthcare issues helped to keep declines in check.
-
*Yum Brands falls as monthly Chinese sales drop. NEW YORK, May 13- U.S. stocks ended flat on Monday, pausing after hitting record highs last week, but strength in healthcare issues helped to keep declines in check.
-
*Core U.S. retail sales rise 0.5 percent in April. *Yum Brands falls as monthly Chinese sales drop. NEW YORK, May 13- U.S. stocks were mostly flat on Monday as investors paused following a rally that took indexes to record highs, though a strong read on retail sales limited declines and the Nasdaq ticked up on a rally in Netflix.
-
*Elan to buy part of U.S. drug firm Theravance's royalty for $1 billion. NEW YORK, May 13- U.S. stocks dipped on Monday, retreating from the most recent record high, but an unexpected rise in retail sales last month muted declines.
-
*Elan, Theravance reach royalties deal. NEW YORK, May 13- U.S. stocks were poised for a lower open on Monday after the S&P 500 index closed at a record high, but an unexpected rise in retail sales last month was likely to curb any decline.
-
*Late payment hitting southern Europe harder than the north. *Business confidence down across Europe. Against the backdrop of the economic downturn and restricted bank lending in Europe, experts fear that the mountain of unpaid bills will drive up insolvency and job losses, reduce cross-border trade and snuff out any recovery.
-
DUBLIN, May 13- Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.